When 340B covered entities contemplate the future, they can find a number of issues to worry about.¬†Here is a thumbnail on some of them. Orphan Drugs There is a possibility that the orphan drug issue will be resolved unfavorably to covered entities. That issue arises out of a 2014¬† court decision, Pharmaceutical Research and Manufacturers … Continue Reading